2014-04-09 16:25:27 -
Avacta Animal Health invites members of the veterinary profession to join its free webinar hosted by CPD solutions on Canine Lymphoma, Current Perspectives on Diagnosis, Treatment and Monitoring on the 24th of April, when leading veterinarian Arno Roos will present the latest thinking on the diagnosis, treatment and monitoring of the disease. The presentation will include an overview of the pathology of lymphoma, diagnosis, chemotherapeutic regimens, and an introduction to Avacta’s SENSITEST® cLBT (canine lymphoma blood test) and its use for diagnostic and monitoring purposes. The capability of this test to differentiate between dogs in remission and those with recurring disease, as well as its potential to aid monitoring of disease status, was recently demonstrated during a blind, retrospective study
of the remission and recurrence responses of canine lymphoma patients treated by chemotherapy1.
Arno Roos obtained a degree in veterinary medicine from Utrecht University, Netherlands, and then trained in oncology and radiotherapy, establishing his veterinary practice as a referral centre for oncological diseases. In 2013, he completed an MSc in clinical oncology at the University of Birmingham, UK, including a dissertation on the use of serum proteomic profiling in the diagnosis and monitoring of dogs with malignant lymphoma. These results, presented at the Veterinary Cancer Society (VCS) conference in Minneapolis, USA, in October last year, demonstrated the very high sensitivity and specificity of the cLBT for diagnosis, as well as its prognostic importance. Arno is a member of the VCS and the European Society of Veterinary Oncology.
To register for the webinar, visit www.caninelymphoma.co.uk
For more information about SENSITEST cLBT, visit www.avactaanimalhealth.com
1Alexandrakis, I., Tuli, R., Ractliffe, S., Tappin, S., Foale, R., Roos, A., Slater, K. Utility of a multiple serum biomarker test to monitor remission status and relapse in 57 dogs undergoing treatment with chemotherapy. Veterinary and Comparative Oncology. In press.